Exactech, Inc. ( EXAC) Q3 2011 Earnings Call November 2, 2011 10:00 a.m. ET Executives Bill Petty – Chairman, CEO David Petty – President Jody Phillips - CFO Analysts William Plovanic – Canaccord Genuity Jeff Johnson – Robert W. Baird James Sidoti – Sidoti & Company Chris Vicini – Eagle Asset Management Mike (Lande) – Summer Street Research Jim Quentin – Barrett & Company Presentation Operator
Previous Statements by EXAC
» Exactech's CEO Discusses Q2 2011 Results - Earnings Call Transcript
» Exactech CEO Discusses Q1 2011 Results - Earnings Call Transcript
» Exactech CEO Discusses Q4 2010 - Earnings Call Transcript
» Exactech CEO Discusses Q3 2010 Results - Earnings Call Transcript
For the third quarter Exactech's revenue were 47.3 million, which is a 13% increase is over the 42 million in the third quarter of 2010. Net income however, was down 12% to 1.3 million, or $0.10 per diluted share compared to 1.5 million or $0.11 per diluted share last year. Excluding the compliances expense of 1 million, the net income increased to 19% to 1.9 million or $0.15 per share.Specifically related to our different product platforms, our Knee Implant revenue for the quarter increased 15% to 17.9 million, Extremity revenue increase 34% to 9.8 million. Hip Implant revenue increased 22% to 8 million. Biologics and Spine revenue however decreased 15% to 5.4 million, and other products were flat at 6.2 million. Now to discuss just briefly the nine-month 2011 performance. For the first nine months, revenue was 152.3 million, which is an increase of 10% compared to the same period last year. Net income for the first nine months was down 10% to 7 million, or $0.53 per-share, compared to 7.8 million or $0.59 per-share in 2010. Excluding the compliance expense, the compliance expense of 3.7 million, net income increased 13% to 9.4 million or $0.71 a share. For the segments for the first nine months, Knee Implant revenue increased 7%, or 59.9 million. Extremity Implant revenue increased 34% to 28.9 million. Hip Implant revenue increased 19% or 24.4 million, and Biologics and Spine revenue decreased 10% to 18.4 million. Our other product revenue increased 2% to 20.7 million. Certainly, we are pleased with our top line performance as we continue to advance our market share. We are not as pleased with the bottom-line performance. Jody will comment a little further on that in a few minutes. These issues were related primarily to shift between domestic and international business, and also some non-recurring expenses, which impacted this to some extent.
So I’m now going to turn it over to Jody, and let Jody give some of the operational and financial information.Joel Phillips Good morning everyone, and thanks for joining us for the third quarter 2011 conference call. The third quarter results were in line with our expectations at the revenue line, but were below our expectations in net income, primarily due to the OUF mix as compared to the U.S. sales, coupled with an increase in cost in our European direct operation. I know that many of you are interested in the currency impact, so I’m going to outline some of those numbers as they relate to the Q3 revenues. When we look at revenues on a constant currency basis for the third quarter, the total revenues were 10% growth versus the reported 13. When we look at knee revenues, that was a 12% constant currency growth versus a reported 15. Hip revenues were 19% constant currency versus a reported 22. Extremity revenues were 33% versus a constant currency 34%. Biospine revenues were down 16% on a constant currency basis versus the reported down of 15%. Our versed margins expanded during the quarter by 110 basis points to 68.5, primarily due to a higher mix of OUF business that was conducted through our direct channels as compared to our traditional distributor base business. As we now begin to annualize the sales ramp up through these direct channels, we expect lower quarter-over-quarter gross margin percentage increases, likely in the neighborhood of 50 to 100 basis points for the fourth quarter of 2011, as well as the first half of 2012. The total operating expense increase of 20% to 30.3 million for the third quarter was impacted by currency conversion as well. Approximately 900,000 of this increase was due to currency on a constant currency basis. The operating expenses increased 17%. The largest driver of the sales and marketing increase was the ramp up of cost in our direct operations in Spain, Germany, and Japan, which accounted for 1.8 million of the $2.3 million increase in sales and marketing expenses for the third quarter. Read the rest of this transcript for free on seekingalpha.com